Incretin Drugs Linked to Gallbladder Disease Risk
-
By
March 14, 2025
-
3 min
-
1
Patients with type 2 diabetes using incretin-based drugs have an increased risk of gallbladder and biliary tract diseases
-
2
Risk remained significant across body mass index categories
-
3
Importance of considering comorbid conditions when prescribing these therapies
-
4
Study acknowledged potential residual confounding and outcome misclassification
-
5
Further studies, including randomized controlled trials, are recommended for a better understanding of this association.
-
A nationwide cohort study analyzed over 1.8 million patients with type 2 diabetes, finding that those using incretin-based drugs had a significantly increased risk of gallbladder and biliary tract diseases. The increased risk was consistent across body mass index categories and remained significant even when balancing baseline characteristics. This study underscores the importance of considering comorbid conditions such as hypertension and liver disease when prescribing these therapies.
-
1
Patients with type 2 diabetes using incretin-based drugs have an increased risk of gallbladder and biliary tract diseases
-
2
Risk remained significant across body mass index categories
-
3
Importance of considering comorbid conditions when prescribing these therapies
-
4
Study acknowledged potential residual confounding and outcome misclassification
-
5
Further studies, including randomized controlled trials, are recommended for a better understanding of this association.
Listen Tab content
